Shanghai Henlius Biotech
Clinical trials sponsored by Shanghai Henlius Biotech, explained in plain language.
-
New immunotherapy combo shows promise for tough lung cancer
Disease control CompletedThis Phase 3 trial tested whether adding an experimental immunotherapy drug called HLX10 to standard chemotherapy could help people with extensive-stage small cell lung cancer live longer. The study enrolled 585 people who had not received prior treatment. Participants were rando…
Phase: PHASE3 • Sponsor: Shanghai Henlius Biotech • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New antibody for lung scarring passes first safety check in healthy volunteers
Disease control CompletedThis study tested a single dose of HLX6018, an experimental antibody, in 66 healthy adults to see if it is safe and how the body handles it. HLX6018 is designed to block a protein pathway involved in idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs. Because thi…
Phase: PHASE1 • Sponsor: Shanghai Henlius Biotech • Aim: Disease control
Last updated Jun 26, 2026 18:59 UTC